Alissa Winzeler
Research Subjects
Alissa Winzeler has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Arushi Agarwal
Health Advances LLC, 275 Grove Street, Newton, MA 02466, USA
1 shared publication - Daryl Pritchard
Personalized Medicine Coalition, Washington, DC 20036, USA
1 shared publication - Gary Gustavsen
Health Advances LLC, Newton, MA 02466, USA
1 shared publication - Hina Mohammed
Syapse Holdings, Inc., Now Part of N-Power Medicine, Redwood City, USA
1 shared publication - Thomas D. Brown
Syapse, San Francisco, CA
1 shared publication
Latest Publications
- Open Access
- 20 September 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (9) , 997
Improvements in Clinical Cancer Care Associated with Integration of Personalized Medicine
Background: While adoption of personalized medicine (PM) continues to increase in clinical oncology, there is limited data connecting the level of PM adoption at a given institution to improved clinical outcomes for patients. The purpose of this study was to analyze the correlation between health care providers’ scores on a previously described PM integration framework and two outcome measures: the use of targeted therapy and clinical trial enrollment. Methods: This study was conducted using real-world data (RWD) from the Syapse® Learning Health Network (LHN). The PM integration score for six community hospital systems in the LHN was calculated and subsequently correlated with the two outcome measures. Results: Across six institutions, a strong correlation between PM integration score and targeted therapy use was observed in metastatic non-small cell lung cancer (mNSCLC) (R2 = 0.81), an indication with a significant number of approved targeted agents. Conversely, a strong correlation between PM integration score and clinical trial enrollment was observed in metastatic triple-negative breast cancer (TNBC) (R2 = 0.63), an indication with fewer marketed targeted therapies but an active targeted therapy pipeline. Conclusion: The results in these cases suggest that PM integration is a strong indicator of high-quality care practices for both utilization of targeted therapy in more mature PM indications (e.g., mNSCLC) and clinical trial enrollment in more emerging PM indications (e.g., TNBC).
- 20 September 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (9) , 997
Open AccessImprovements in Clinical Cancer Care Associated with Integration of Personalized Medicine
Background: While adoption of personalized medicine (PM) continues to increase in clinical oncology, there is limited data connecting the level of PM adoption at a given institution to improved clinical outcomes for patients. The purpose of this study was to analyze the correlation between health care providers’ scores on a previously described PM integration framework and two outcome measures: the use of targeted therapy and clinical trial enrollment. Methods: This study was conducted using real-world data (RWD) from the Syapse® Learning Health Network (LHN). The PM integration score for six community hospital systems in the LHN was calculated and subsequently correlated with the two outcome measures. Results: Across six institutions, a strong correlation between PM integration score and targeted therapy use was observed in metastatic non-small cell lung cancer (mNSCLC) (R2 = 0.81), an indication with a significant number of approved targeted agents. Conversely, a strong correlation between PM integration score and clinical trial enrollment was observed in metastatic triple-negative breast cancer (TNBC) (R2 = 0.63), an indication with fewer marketed targeted therapies but an active targeted therapy pipeline. Conclusion: The results in these cases suggest that PM integration is a strong indicator of high-quality care practices for both utilization of targeted therapy in more mature PM indications (e.g., mNSCLC) and clinical trial enrollment in more emerging PM indications (e.g., TNBC).